Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors

Thromb Haemost. 2019 Nov;119(11):1886-1887. doi: 10.1055/s-0039-1695769. Epub 2019 Oct 10.

Authors

Sébastien Miranda¹, Ygal Benhamou¹, Philip Wells², Marc Carrier²

Affiliations

¹ Department of Internal Medicine, Vascular and Thrombosis Unit, Rouen University Hospital, Normandie University, UNIROUEN, INSERM U1096, Rouen, France.
² Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

PMID: 31600806
DOI: 10.1055/s-0039-1695769

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Aged
Astrocytoma / complications
Astrocytoma / drug therapy*
Brain Neoplasms / complications
Brain Neoplasms / drug therapy*
Female
Fibrinolytic Agents / therapeutic use*
Glioblastoma / complications
Glioblastoma / drug therapy*
Humans
Male
Middle Aged
Neoplasm Metastasis
Pulmonary Embolism / etiology
Pulmonary Embolism / prevention & control*
Pyrazoles / therapeutic use*
Pyridones / therapeutic use*
Treatment Outcome
Venous Thrombosis / etiology
Venous Thrombosis / prevention & control*

Substances

Fibrinolytic Agents
Pyrazoles
Pyridones
apixaban